Thanks for signing up for DividendStocks.com! It's the daily newsletter built for dividend and income investors. Before we can begin sending your daily updates, there’s one quick step left. Please confirm your subscription using the link below so our emails reach your inbox. Click Here to Confirm Your Subscription to DividendStocks.com Here’s a small glimpse of what you’ll get access to: Dividend Stock Ideas — Each newsletter features dividend stocks with high yields, sustainable payouts, and strong growth potential. Ex-Dividend Stocks — Want to capture upcoming dividend payouts? Find out which stocks are going ex-dividend this week. Market News and Events — Stay in the loop on the latest developments impacting popular dividend names like AT&T, Exxon Mobil, IBM, Procter & Gamble, and Verizon. Bonus: As a thank-you for confirming, you’ll also receive a free PDF copy of Automatic Income, our popular guide to building wealth through dividend investing. Let’s get your dividend journey started! Discover Top Income-Generating Stocks Here See you in your inbox soon,
The DividendStocks.com Team P.S. Don’t miss out click here to verify your subscription and secure your daily dividend insights and your free investing guide!
Today's Exclusive Story Pfizer Pops on Q4 Results—But This May Be the Catalyst That Matters MostAuthored by Chris Markoch. First Published: 2/5/2026. 
At a Glance - Pfizer stock jumped after a beating on the top and bottom lines, but the rally may reflect more than just strong quarterly results and short-term GLP-1 excitement.
- Positive Phase 2b GLP-1 obesity data gives Pfizer optionality, though meaningful revenue from weight-loss drugs is still several years away.
- An expanding oncology pipeline and AI-driven R&D strategy could be the most overlooked long-term growth catalysts for PFE.
Pfizer Inc. (NYSE: PFE) helped lift the Dow Jones Industrial Average (DJIA) the day after delivering a double beat in its fourth-quarter earnings report. Revenue of $17.56 billion topped analysts' estimates of $16.93 billion. On the bottom line, Pfizer reported adjusted earnings per share (EPS) of $0.69, beating estimates of $0.57. Highlighting the report was Pfizer's announcement of positive topline results from the Phase 2b study for its lead GLP-1 candidate. Watch Now! Porter Stansberry & Luke Lango join forces to unveil:
The Three Titanic Forces Converging To Unleash A New 1776 Moment
"We have never seen wealth created at this size and speed" MIT Researcher Click here for the stocks to buy and sell now PFE stock closed up 4% on Feb. 4 as analysts and investors digested the results. The bullish thesis is that while GLP-1 headlines may drive near-term excitement, Pfizer's more durable upside is likely to come from its expanding oncology pipeline and its accelerating use of artificial intelligence across R&D. That story begins with the company's push into obesity, where it reported a notable clinical update alongside the quarter. Pfizer Wants a Piece of the Weight-Loss Drug Pie The weight-loss drug market is growing rapidly. Data show the global GLP-1 market expanding from $62.2 billion in 2025 to $157 billion by 2035, a compound annual growth rate (CAGR) of about 9.7%. That growth is attracting billions of dollars from companies trying to carve out market share. For Pfizer, the opportunity centers on its lead GLP-1 candidate, MET-097i. The company announced results from its Phase 2b VESPER-3 study, which met its primary endpoint and showed a statistically significant, placebo-adjusted weight loss of up to 12.3% at 28 weeks. Pfizer also noted that patients continued to lose weight after switching from weekly to monthly dosing, with no plateau observed by week 28. The Growth Driver Investors May Be Missing Immediately after the report, conventional wisdom attributed the stock's gain to the positive GLP-1 data. That may be true, but investors should view that as a near-term catalyst rather than the entirety of Pfizer's upside. While Pfizer's GLP-1 candidate shows promise, it will take time for those results to meaningfully impact the company's revenue. Moreover, the GLP-1 trade is becoming more competitive — as seen in recent results from Eli Lilly & Co. (NYSE: LLY), which isn't ceding its leadership in obesity drugs. There are, however, other compelling reasons to be bullish on PFE — notably its oncology portfolio. Business Research Insights estimates the global oncology drugs market at roughly $264.92 billion in 2026, projected to climb to $648.08 billion by 2035, a CAGR of about 10.3%. A Growing Pipeline Gives Pfizer Many Shots on Goal As of late 2025, Pfizer had roughly 60 candidates in its product portfolio, offering many opportunities to capture market share. The portfolio was significantly bolstered by its acquisition of Seagen in 2023. Today, Pfizer's pipeline includes late-stage candidates such as vepdegestrant, a next-generation targeted protein degrader (PROTAC), paired with atirmociclib, a selective CDK4 inhibitor targeting ER+/HER2- metastatic breast cancer. Pfizer also has other late-stage candidates, including: - Sigvotatug vedotin, an antibody-drug conjugate (ADC) in Phase 3 testing (e.g., Be6A LUNG-01) for metastatic non-small cell lung cancer, leveraging Pfizer's Seagen-acquired ADC expertise.
- Sasanlimab, which targets bladder cancer, and a bispecific PD-1xVEGF agent (PF-4404) that is being tested in combination with Padcev for urothelial cancer — positioning these programs as potential blockbusters amid oncology growth.
Beyond having multiple drugs that could reach the market over the next five to 10 years, Pfizer's commitment to artificial intelligence (AI) is another differentiator in the biopharmaceutical sector. Pfizer integrates AI across R&D through partnerships like Boltz for biomolecular modeling, XtalPi for molecular design, and Data4Cure for oncology analytics. These tools can speed target identification by at least 50% with platforms such as OncoScout. Internally, platforms like "Charlie" handle data mining, predictions, and content generation, and collaborations with NVIDIA (NASDAQ: NVDA) help optimize discovery and manufacturing. These AI efforts supported Pfizer's rapid development of Paxlovid and underpin anticipated 2026 catalysts in oncology and obesity. The company is targeting $1.2 billion in savings by 2027 through efficiency gains. Industry-wide, AI is expected to boost productivity by 35% to 45% by improving preclinical decisions and trial design, making it a core competitive advantage rather than optional hype. Pfizer's leading position in AI adoption should be a meaningful tailwind for investors over the medium and long term.
| 
